Treatment of Histoplasmosis with MK-991 (L-743,872)

AUTOR(ES)

Graybill, John R.

FONTE

American Society for Microbiology

RESUMO

BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

Documentos Relacionados

• Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models of Pneumocystis carinii
• Treatment of murine disseminated candidiasis with L-743,872.
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
• Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
• Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.